Linghui Zhou1,2,3,4, Qin Yu5, Guoqing Wei1,2,3,4, Linqin Wang1,2,3,4, Yue Huang1,2,3,4, Kejia Hu1,2,3,4, Yongxian Hu6,7,8,9, He Huang10,11,12,13. 1. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. 2. Institute of Hematology, Zhejiang University, Hangzhou, China. 3. Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. 4. Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China. 5. College of Life Science, Zhejiang Chinese Medical University, Hangzhou, China. 6. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. 1313016@zju.edu.cn. 7. Institute of Hematology, Zhejiang University, Hangzhou, China. 1313016@zju.edu.cn. 8. Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. 1313016@zju.edu.cn. 9. Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China. 1313016@zju.edu.cn. 10. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. huanghe@zju.edu.cn. 11. Institute of Hematology, Zhejiang University, Hangzhou, China. huanghe@zju.edu.cn. 12. Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. huanghe@zju.edu.cn. 13. Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, China. huanghe@zju.edu.cn.
Abstract
BACKGROUND: Multiple myeloma (MM) is a major health concern. Understanding the different burden and tendency of MM in different regions is crucial for formulating specific local strategies. Therefore, we evaluated the epidemiologic patterns and explored the risk factors for MM death. METHODS: Data on MM were collected from the 2019 Global Burden of Disease study. We used incidence, mortality, and disability adjusted life-years to estimate the global, regional, and national burden of MM. RESULTS: In 2019, there were 155,688 (95% UI, 136,585 - 172,577) MM cases worldwide, of which 84,516 (54.3%, 70,924 - 94,910) were of men. The age-standardized incidence rate (ASIR) was 1.72/100,000 persons (95% UI, 1.59-1.93) in 1990 and 1.92/100,000 persons (95% UI, 1.68-2.12) in 2019. The number of MM deaths increased 1.19-fold from 51,862 (95% UI, 47,710-58,979) in 1990 to 113,474 (95% UI, 99,527 - 121,735) in 2019; the age-standardized death rate (ASDR) was 1.42/100,000 persons (95% UI, 1.24-1.52) in 2019. In recent 15 years, ASDR showed a steady tendency for men, and a downward tendency for women. Countries with high social-demographic indexes exhibited a higher ASIR and ASDR. Australasia, North America, and Western Europe had the highest ASIR and ASDR, with 46.3% incident cases and 41.8% death cases. Monaco had the highest ASIR and ASDR, which was almost half as high as the second highest country Barbados. In addition, United Arab Emirates and Qatar had the largest growth multiple in ASIR and ASDR, which was twice the third country Djibouti. CONCLUSIONS: Globally, incident and death MM cases have more than doubled over the past 30 years. The increasing global burden may continue with population aging, whereas mortality may continue to decrease with the progression of medical technology. The global burden pattern of MM was diverse, therefore specific local strategies based on different burden patterns for MM are necessary.
BACKGROUND:Multiple myeloma (MM) is a major health concern. Understanding the different burden and tendency of MM in different regions is crucial for formulating specific local strategies. Therefore, we evaluated the epidemiologic patterns and explored the risk factors for MM death. METHODS: Data on MM were collected from the 2019 Global Burden of Disease study. We used incidence, mortality, and disability adjusted life-years to estimate the global, regional, and national burden of MM. RESULTS: In 2019, there were 155,688 (95% UI, 136,585 - 172,577) MM cases worldwide, of which 84,516 (54.3%, 70,924 - 94,910) were of men. The age-standardized incidence rate (ASIR) was 1.72/100,000 persons (95% UI, 1.59-1.93) in 1990 and 1.92/100,000 persons (95% UI, 1.68-2.12) in 2019. The number of MM deaths increased 1.19-fold from 51,862 (95% UI, 47,710-58,979) in 1990 to 113,474 (95% UI, 99,527 - 121,735) in 2019; the age-standardized death rate (ASDR) was 1.42/100,000 persons (95% UI, 1.24-1.52) in 2019. In recent 15 years, ASDR showed a steady tendency for men, and a downward tendency for women. Countries with high social-demographic indexes exhibited a higher ASIR and ASDR. Australasia, North America, and Western Europe had the highest ASIR and ASDR, with 46.3% incident cases and 41.8% death cases. Monaco had the highest ASIR and ASDR, which was almost half as high as the second highest country Barbados. In addition, United Arab Emirates and Qatar had the largest growth multiple in ASIR and ASDR, which was twice the third country Djibouti. CONCLUSIONS: Globally, incident and death MM cases have more than doubled over the past 30 years. The increasing global burden may continue with population aging, whereas mortality may continue to decrease with the progression of medical technology. The global burden pattern of MM was diverse, therefore specific local strategies based on different burden patterns for MM are necessary.
Entities:
Keywords:
Death; Disability adjusted life-years; Global burden of disease; Incidence; Multiple myeloma
Authors: Matthew Tsang; Michelle Le; Feras M Ghazawi; Janelle Cyr; Akram Alakel; Elham Rahme; François Lagacé; Elena Netchiporouk; Linda Moreau; Andrei Zubarev; Osama Roshdy; Steven J Glassman; Denis Sasseville; Gizelle Popradi; Ivan V Litvinov Journal: Cancer Date: 2019-04-05 Impact factor: 6.860
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; L Joseph Melton Journal: Cancer Date: 2004-12-01 Impact factor: 6.860
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Zaiwei Song; Lan Ma; Li Bao; Yi Ma; Ping Yang; Dan Jiang; Aijun Liu; Lu Zhang; Yan Li; Yinchu Cheng; Fei Dong; Rongsheng Zhao; Hongmei Jing Journal: Front Pharmacol Date: 2022-06-23 Impact factor: 5.988
Authors: Nitya Nathwani; Jill Bell; Dasha Cherepanov; France Ginchereau Sowell; Rachel Shah; Kelly McCarrier; Parameswaran Hari Journal: Support Care Cancer Date: 2022-04-01 Impact factor: 3.359
Authors: Meletios A Dimopoulos; Joseph Mikhael; Evangelos Terpos; Xavier Leleu; Philippe Moreau; Joan Bladé; Jin Seok Kim; Keith Stockerl-Goldstein; Paul G Richardson Journal: Ther Adv Hematol Date: 2022-04-02
Authors: Ahmad S Alsaeed; Mona J Najib; Sameer M Al Amoudi; Ihab Y Elhemaidi; Ahmed A Absi; Majed D Al Ahmadi; Saleem K Eldadah; Walaa A Rajkhan; Manar M Khalil; Mohammed H Almohammadi Journal: Saudi Med J Date: 2022-06 Impact factor: 1.422
Authors: Catharina Muylaert; Lien Ann Van Hemelrijck; Anke Maes; Kim De Veirman; Eline Menu; Karin Vanderkerken; Elke De Bruyne Journal: Front Oncol Date: 2022-08-18 Impact factor: 5.738